2019 - PRESS RELEASES
Myonexus Therapeutics recieves orphan drug designation for Myo-102 - Myonexus January 2nd 2019
Myonexus Therapeutics announces accelerated acquisition by Sarepta Therapeutics. - 2019
Clinical Update: Myo-101 For LGMD Type 2E Business update: Myonexus Acquisition - Sarepta - february 27 2019
Distrofia dei cingoli, Sarepta decide di acquisire Myonexus - Osservatorio Malattie Rare - march 12 2019
Distrofia dei cingoli 2E, primi risultati clinici favorevoli per la terapia genica - Osservatorio Malattie Rare OMAR - April 12 2019
How an Ohio Kids hospital Quitly Became Groung Zero for Gene Therapy - Xconomy - april 15 2019
Gene Delivery for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) by Isolated Limb Infusion - PubMed.gov - July 2019
La terapia genica SRP-9003 mostra risultati molto incoraggianti a 9 mesi nella distrofia dei cingoli - Sarepta Reports - October 9 2019
Distrofia dei cingoli 2E, nuovi risultati positivi per la terapia genica SRP-9003 - Osservatorio Malattie Rare OMAR - October 22 2019
- Hits: 1805